Cleavage of a membrane-bound transcription factor by the chemotherapeutic reagent doxorubicin can block the proliferation of tumor cells.

Mutagenesis studies identified an androgen receptor mutation that converts enzalutamide-a drug recently approved for the treatment of advanced prostate cancer-into an androgen receptor agonist, and modeling studies informed the design of novel drugs that are effective against the mutant receptor.

A protein called PVRL4 has a central role in a number of cancers that originate in epithelial tissue, and anti-PVRL4 antibodies could be used to treat some of these cancers.

The receptor EBI2 is essential for correctly positioning CD4+ dendritic cells in the spleen so that they can present blood-borne antigens to T cells and thereby provoke an antibody response.

C-terminal phosphorylation of the lipid phosphatase PTEN drives a reduction in membrane affinity and leads to a more compact conformation that involves a C2 domain-tail interaction.

Reduced expression of MYBL2 contributes to malignancies of the blood by permitting uncontrolled expansion of blood cell progenitors, implying a tumor suppressor function for this gene.

A long non-coding RNA regulates the expression of genes that encode proteins involved in the inflammatory response.

A cell-free system combined with cell-based assays elucidate the biochemical mechanism of signal transduction mediated by the mitochondrial protein MAVS and delineates the role of ubiquitin E3 ligases in antiviral innate immune responses.

The intestine contains distinct subregions specialized for digestion along its anterior-posterior axis, and the stem cells that constantly renew these subregions are not interchangeable.

A comprehensive study of human transcription factors reveals that a greater number of these proteins bind to methylated DNA sequences than previously thought.